Merck & Co Inc (MRK) Common Stock USD0.50
- Add to watchlist
- This stock can be held in a
Share news, reports & tips
-
US close: Stocks recover from three days of losses
28 March 2024 00:12
(Sharecast News) - Shares on Wall Street showed signs of recovery on Wednesday, with all major indices edging higher amidst low trading volumes following three consecutive down sessions.
-
US close: Stocks bounce back as labour market softens
2 February 2024 00:21
(Sharecast News) - Wall Street equities experienced a notable rebound on Thursday, bouncing back from a significant sell-off in the previous session.
-
Moderna shares surge on cancer trial combo with Merck treatment
14 December 2023 12:13
(Sharecast News) - Shares in Moderna surged on Thursday after trial results of its experimental cancer vaccine, used in conjunction with Merck's Keytruda treatment, reduced the risk of death or relapse...
-
Merck to buy Caraway Therapeutics for up to $610m
21 November 2023 11:22
(Sharecast News) - Merck said on Tuesday that it has agreed to buy preclinical biopharmaceutical group Caraway Therapeutics for up to $610m.
-
Merck beats on Q1 earnings amid 'strong underlying performance'
27 April 2023 12:39
(Sharecast News) - Global pharmaceuticals firm Merck said in its first-quarter earnings on Thursday that, despite a 9% decrease in total worldwide sales year-on-year to $14.49bn, it saw a "strong...
-
Merck & Co. posts stronger-than-expected Q4 numbers, guidance falls short
2 February 2023 13:09
(Sharecast News) - Merck & Co. posted better-than-expected quarterly results despite stiff foreign exchange headwinds, but its guidance for profits fell short of Wall Street estimates.
-
Moderna Covid vaccine sales top $18bn
9 January 2023 12:18
(Sharecast News) - US biotech Moderna said on Monday that it sold more than $18bn of Covid-19 vaccines last year.
-
FDA gives AstraZeneca extension on cancer drug application
15 December 2022 07:49
(Sharecast News) - The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
-
Merck to buy Imago BioSciences in $1.35bn deal
21 November 2022 11:20
(Sharecast News) - Merck has agreed to buy cancer drug developer Imago BioSciences in a $1.35bn deal.
-
Merck beats Q4 forecasts amid broad jump in sales
3 February 2022 13:31
(Sharecast News) - Merck blasted past analysts' estimates for its fourth quarter earnings, helped by sales of its new Covid-19 treatment Molnupiravir.
-
Merck&Co. says oral Covid-19 treatment cuts risk of hospitalisation or death by 30%
26 November 2021 12:09
(Sharecast News) - Merck&Co. and development partner Ridgeback Biotherapeutics announced that their experimental oral treatment against Covid-19 reduced the risk of hospitalisation or death by nearly one...
-
Merck and Ridgeback file with FDA for emergency approval of Covid-19 medicine
11 October 2021 12:42
(Sharecast News) - Merck and Ridgeback Biotherepautics have filed for Emergency Use Approval of their oral antiviral for mild-to-moderate cases of Covid-19 with America's lead regulator, the U.S. Food...
Company announcements Announcements
No company announcements about Merck & Co Inc Common Stock USD0.50 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.